As of November, 112 Zofran birth defect lawsuits are pending in multidistrict litigation.
Lawsuits filed over alleged birth defects suffered by infants exposed to the anti-nausea drug in the womb number 112 and will likely continue to rise. These cases are included in the current Boston multidistrict litigation concerning Zofran, number 2657. Zofran was developed by pharmaceutical giant GlaxoSmithKline, and was approved by the FDA in 1991 specifically to treat patients who were suffering from nausea and vomiting associated with chemotherapy, radiation, or anesthesia. The drug was never approved for or tested for safety on pregnant women, yet was allegedly marketed to this consumer group and to OB/Gyns across the nation by GSK. Since this time, it has been prescribed to an estimated 1 million pregnant women annually according to the American Journal of Obstetrics and Gynecology, and has become the topic of many lawsuits indicating that exposure to the drug through their mothers caused babies in the womb to develop birth defects. MDL consolidation for the cases currently involved was originally established by the JPML on October 13th. Since this time all cases regarding Zofran birth defect lawsuits have been transferred to Boston, Massachusetts to join the MDL. The suits similarly allege that common birth defects connected to exposure to the drug in unborn babies are cleft lip and palate, atrial septal defect and ventricular septal defect, transposition of the greater vessels, and kidney defects. Several plaintiffs involved report that their infants were born with defects so severe they were fatal. Almost all plaintiffs note that their infants required multiple surgeries in an attempt to repair their defects. Originally posted by Michael Monheit on DigitalJournal.com. Zofran Birth Defect Lawsuits – Ball & Evans & Ball & Evans Trial Attorney – Los Angeles